Physician profile
Jon C Jackson
NPI 1760669345
$833,744.34
in general payments reported to CMS, 2019-2025
20 companies · $206K in 2025
The $206K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $63K · 2021: $57K · 2022: $66K · 2023: $148K · 2024: $187K · 2025: $206K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $456K · Travel and Lodging: $56K · Consulting Fee: $15K · Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $456,047.00 |
| Travel and Lodging | $56,025.29 |
| Consulting Fee | $14,810.00 |
| Food and Beverage | $14,674.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $636,477.21 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $193,789.57 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $693.42 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $602.32 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $389.03 | 2019-2023 | Invega Sustenna |
| Lundbeck LLC | $327.13 | 2019-2023 | Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $248.02 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $221.69 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $202.79 | 2019-2025 | Fanapt |
| Allergan, INC. | $152.10 | 2019-2020 | |
| Greenwich Biosciences, INC. | $132.38 | 2019 | |
| Sunovion Pharmaceuticals INC. | $118.99 | 2019-2020 | |
| Bioxcel Therapeutics, INC. | $97.16 | 2023 | Igalmi |
| Avanir Pharmaceuticals, INC. | $95.09 | 2019-2022 | |
| Abbvie INC. | $51.45 | 2023-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $48.96 | 2021 | |
| Ironshore Pharmaceuticals INC. | $40.35 | 2019 | |
| Indivior INC. | $20.11 | 2023 | Perseris |
| Ucb, INC. | $18.86 | 2019 | |
| Stryker Corporation | $17.71 | 2023 | Procuity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.